126P - Serum markers of bone remodeling in patients with advanced non-small cell lung cancer and bone metastases

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Non-Small-Cell Lung Cancer, Metastatic
Translational Research
Presenter Franco Lumachi
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors F. Lumachi1, F. Mazza2, A. Del Conte3, G.B. Chiara4, S.M.M. Basso4
  • 1Department Of Surgery, Oncology & Gastroenterology, University of Padua, School of Medicine, 35128 - Padova/IT
  • 2Pneumology, S. Maria degli Angeli Hospital, 33170 - Pordenone/IT
  • 3Medical Oncology, S. Maria degli Angeli Hospital, 33170 - Pordenone/IT
  • 4Surgery 1, S. Maria degli Angeli Hospital, 33170 - Pordenone/IT


Lung cancer is the most common cause of cancer death worldwide. In the USA, there were estimated to be 246,000 new cases and 164,000 deaths in 2013. Approximately, 80 % of lung cancers are carcinomas that are classified histologically as non-small cell lung cancer (NSCLC). The efficacy control for the treatment of bone metastases in NSLCLC is difficult and usually initiated later and with longer time between treatment cycles than the restaging of visceral or soft tissue metastases. The aim of this study was to evaluate the usefulness of bone formation serum markers bone alkaline phosphatase (bALP) and osteoprotegerin (OPG), and bone resorption serum markers tartrate-resistant acid phosphatase isoform-5b (TRACP 5b), carboxy terminal cross-linked telopeptide of type I collagen (CTX), and receptor activator of nuclear factor-κ ligand (RANKL) in patients with NSCLC and bone metastases.